glp 1 type 2 diabetes New GLP-1 Guidelines for in 2025 GLP-1 receptor agonists in the

It is not intended for clinical or therapeutic use outside regulated scientific studies

doi: 10.1196/annals.1427.014 113 DavidKKAndrabiSADawsonTMDawsonVL

The study titled Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice and published in Hormone and Metabolic Research indicates that 58% of patients reported side effects mostly concerning the gastrointestinal tract. In addition, more than 20% of the participants quit the drug because of intolerable side effects. This study certainly put Novo Nordisk on risk of bowel injuries associated with the use of Ozempic

This is especially relevant in PCOS, because the condition itself elevates baseline gestational diabetes risk (Moran et al